• Citer

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

par van Herpen, C M L;Locati, L D;Buter, J;Thomas, José;Bogaerts, J;Lacombe, Denis;de Mulder, Pieter;Awada, Ahmad ;Licitra, L;Bernier, J;Vermorken, Jan Baptist
Référence European journal of cancer, 44, 17, page (2542-2545)
Publication Publié, 2008-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

BACKGROUND: This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). PATIENTS AND METHODS: Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m(2) intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. RESULTS: Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. CONCLUSION: We conclude that gemcitabine is not an active drug in ACC.